IL2RA and neoplasm: Notably, this next-generation IL-2 drug preferentially binds CD122 (and shows no CD25 affinity) on immune cells and acts as a powerful switch for activating and proliferating tumor-killing effector NK and T lymphocytes to fight cancer (46).